NX-1207 is also being evaluated for the treatment of low risk localized prostate cancer where NX-1207 is administered directly into the area of the prostate where the cancer was detected. A U.S. Phase 2 study (NX03-0040) for that indication is in progress.

More information about Nymox is available at www.nymox.com , email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Development of drug products involves substantial risks and actual results may differ materially from expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.
CONTACT: For Further Information Contact:         Brian Doyle         Nymox Pharmaceutical Corporation         1-800-93NYMOX         www.nymox.com

If you liked this article you might like

The Pockets of Speculative Action Have Dried Up

Jabbing a Needle in the Overinflated Nymox Prostate Drug Hype

These 5 Stocks Under $10 Could Make You a Lot of Money

Nymox Pharmaceuticals (NYMX) Stock Surges on Long-Term Prostate Drug Trial Success

Nymox Pharmaceuticals (NYMX) Stock Surges on Prostate Drug Progress